Lumavita is a specialty biopharmaceutical company located in Basel, Switzerland, and dedicated to the development of anti-infective drugs for women’s health. Lumavita’s portfolio consists of LMV-601, a first-in-class anti-viral compound (treatment of Human Papilloma Virus infections leading to cervix cancer) currently in Phase I, and LMV-602 (pentamycin), foreseen to cure vaginitis caused by both candida and trichomonas.

Company Info
Country: Switzerland
Industry:    Biotech
Sector: biotechnology
Status: Realized
Vehicle: Endeavour II LP

Company website

Endeavour Vision Team
Olivier Valdenaire
Sven Lingjaerde
© Endeavour Vision SA 2006-2017 Terms & Conditions